Key Points
- Nuvalent CEO James Richard Porter sold 30,000 shares on May 4 for $3,050,700 (avg. $101.69), trimming his stake by 8.45% to 324,879 shares; he also sold 30,000 shares on April 6 for $3,113,100.
- Nuvalent reported Q results on May 7 with EPS of ($1.39), missing the consensus ($1.35) by $0.04, and analysts forecast a -5.65 EPS for the current fiscal year.
- The stock has a market cap of $8.20 billion, a 12‑month range of $63.56–$113.01, a consensus rating of "Moderate Buy" with a $137.25 price target, and roughly 97.26% of shares are held by institutional investors.
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 30,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $101.69, for a total value of $3,050,700.00. Following the transaction, the chief executive officer directly owned 324,879 shares of the company's stock, valued at approximately $33,036,945.51. This trade represents a 8.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
James Richard Porter also recently made the following trade(s):
- On Monday, April 6th, James Richard Porter sold 30,000 shares of Nuvalent stock. The stock was sold at an average price of $103.77, for a total value of $3,113,100.00.
Nuvalent Trading Up 2.7%
Shares of NUVL stock opened at $104.26 on Thursday. The company has a market cap of $8.20 billion, a price-to-earnings ratio of -17.82 and a beta of 1.15. The stock has a 50 day simple moving average of $101.99 and a 200-day simple moving average of $102.28. Nuvalent, Inc. has a 12-month low of $63.56 and a 12-month high of $113.01.
Nuvalent (NASDAQ:NUVL - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.04). On average, equities analysts forecast that Nuvalent, Inc. will post -5.65 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on NUVL. Wedbush reissued an "outperform" rating and set a $125.00 target price on shares of Nuvalent in a research note on Wednesday, April 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvalent in a research note on Tuesday, April 21st. HC Wainwright restated a "buy" rating and issued a $155.00 price target on shares of Nuvalent in a report on Tuesday, April 21st. Wells Fargo & Company initiated coverage on Nuvalent in a report on Monday, March 30th. They issued an "overweight" rating and a $116.00 price target on the stock. Finally, Cantor Fitzgerald upped their price target on Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Friday, February 27th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Nuvalent presently has an average rating of "Moderate Buy" and a consensus price target of $137.25.
View Our Latest Report on NUVL
Institutional Investors Weigh In On Nuvalent
A number of institutional investors and hedge funds have recently modified their holdings of NUVL. RA Capital Management L.P. acquired a new stake in Nuvalent during the 3rd quarter valued at $107,794,000. Wellington Management Group LLP grew its holdings in Nuvalent by 46.0% during the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company's stock valued at $198,979,000 after buying an additional 724,491 shares during the last quarter. Vanguard Group Inc. grew its holdings in Nuvalent by 13.9% during the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company's stock valued at $527,521,000 after buying an additional 639,264 shares during the last quarter. Norges Bank acquired a new stake in Nuvalent during the 4th quarter valued at $57,763,000. Finally, JPMorgan Chase & Co. grew its holdings in Nuvalent by 32.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company's stock valued at $221,826,000 after buying an additional 545,542 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company's stock.
About Nuvalent
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
